Overview

Solid Dosage Formulations

We are engaged in the development, manufacture, sale and distribution of prescription generic pharmaceutical products principally in the United States, and with a growing presence in Europe, Canada, Japan, Australia, as well as the rest of the world. We focus primarily on the manufacture and sale of solid dosage formulations for CVS, CNS, GI and anti-allergy therapeutic categories. The business derives benefit from backward integration into our API business. Experienced in developing over 100 molecules across therapeutic categories of CVS, CNS, Antiinfective, Pain, Respiratory and Antidiabetic.

  • Multiple dosage form / containment capabilities
    • Immediate release oral solids
    • Modified release oral solids
    • Steroids
    • Potential for liquids, ointments, powders, opthalmic and injectables
    • Experience in developing formulations forveterinary business
  • A leading formulations player- Development, manufacture and sale of proprietary Dosage Formulations
  • Creating differential dosage forms with MUPS based products, ODT, chewable tablets Powder For Oral Suspension etc.
  • Capable of developing multiple products per annum for various geographies like USA, EU, Canada, Japan, China, Australia, Brazil & ROW Markets
  • In-house USFDA and other key regulatory agencies audited BA BE unit
  • In the United States market, since we commenced operations through to June 30, 2018, we have made a total of 95 ANDA filings for solid dosage formulations, of which 35 are pending approval.
  • As at June 30, 2018, we had 53 commercialized generic solid dosage formulations products across the United States, Europe, Canada, Australia and the rest of the world.
  • Our in-house API capability provides us stable source of API supply for availability of these products at competitive prices